Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy (Q46244368)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/18547621

Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/18547621

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

8

object named as

C Blake Gilks

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/18547621

author name string

Joshua Z Press

1

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/18547621

Jennifer A Kenyon

2

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/18547621

Hui Xue

3

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/18547621

Melinda A Miller

4

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/18547621

Alessandro De Luca

5

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/18547621

Dianne M Miller

6

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/18547621

David G Huntsman

7

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/18547621

Jessica N McAlpine

9

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/18547621

Y Z Wang

10

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/18547621

language of work or name

0 references

publication date

10 June 2008

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/18547621

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/18547621

110

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/18547621

2

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/18547621

256-264

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/18547621

Cancer of the ovary

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.011

7 January 2021

Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.011

7 January 2021

Human Tumor Xenografts as Predictive Preclinical Models for Anticancer Drug Activity in Humans: Better than Commonly Perceived—But They Can Be Improved

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.011

7 January 2021

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.011

7 January 2021

Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.011

7 January 2021

Mouse models of gynecologic pathology

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.011

7 January 2021

Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.011

7 January 2021

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.011

7 January 2021

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.011

7 January 2021

Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.011

7 January 2021

Significance analysis of microarrays applied to the ionizing radiation response

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.011

7 January 2021

Morphological effects of chemotherapy on ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.011

7 January 2021

Histopathologic assessment of tumor regression after neoadjuvant chemotherapy in advanced-stage ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.011

7 January 2021

Histopathologic assessment of chemotherapy effects in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.011

7 January 2021

Clinicopathologic features of BRCA-linked and sporadic ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.011

7 January 2021

Targeting the DNA repair defect of BRCA tumours

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.011

7 January 2021

The therapeutic effects of PJ34 [N-(6-oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide.HCl], a selective inhibitor of poly(ADP-ribose) polymerase, in experimental allergic encephalomyelitis are associated with immunomodulation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.011

7 January 2021

Anti-inflammatory effects of a novel, potent inhibitor of poly (ADP-ribose) polymerase

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.011

7 January 2021

Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.011

7 January 2021

Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.011

7 January 2021

Identifiers

10.1016/J.YGYNO.2008.03.011

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/18547621

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/18547621

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46244368&oldid=2102091388"